Results 201 to 210 of about 1,391,256 (255)

Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial

The Prostate, EarlyView.
ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento, Hui‐Ming Lin, Nicole Yeung, Rachel M.N. Kim, Neil Portman, Martin R. Stockler, Andrew J. Martin, Vinod Subhash, Sonia Yip, Lisa M. Butler, Ian C. Marschner, Peter J. Meikle, Arun A. Azad, Ian D. Davis, Lisa G. Horvath, Christopher J. Sweeney   +15 more
wiley   +1 more source

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki, Jennifer La, Danne C. Elbers, Nhan V. Do, Channing J. Paller, Nathanael R. Fillmore, Martin W. Schoen   +6 more
wiley   +1 more source

Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial. [PDF]

J Clin Oncol
Okano S, Tahara M, Tsukahara K, Otsuka T, Kano S, Nagaoka M, Uryu H, Sano D, Nishio N, Ono K, Ohkoshi A, Hanazawa T, Shinoda S, Takeda Y, Yamamoto K, Kiyota N.   +15 more
europepmc   +1 more source

Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy

The Prostate, EarlyView.
ABSTRACT Background Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic ...
Cem Onal, Gurcan Erbay, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler   +4 more
wiley   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source

Androgen receptor expression in glioblastoma: molecular profiling and association with tumor burden. [PDF]

Mol Biol Rep
Liubych L, Hahn L, Hollnagel R, Streubel MK, Ailani D, Leppert J, Krenzlin H, Matschke J, Soltwedel C, Borgardt N, Behling S, Zemskova O, Ditz C, Gebauer N, Kebenko M, Keric N, Lapshyna O, Gemoll T, Carl C, Neumann A, Rades D, Löser A.   +21 more
europepmc   +1 more source

Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential

Phytotherapy Research, EarlyView.
Schematic overview of bone remodeling dysregulation in osteoporosis and the multi‐target protective role of herbal therapeutics. ABSTRACT Osteoporosis is a chronic bone disease marked by reduced density and increased fracture risk. Current treatments face limitations in safety, efficacy, and long‐term adherence, prompting interest in alternative ...
Elnaz Vafadar Moradi, Sina Vossoughinia, Zahra Yazdanpanah, Hossein Sobhani, Jalileh Jalali, Mahboobeh Ghasemzadeh Rahbardar   +5 more
wiley   +1 more source

Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities. [PDF]

Front Oncol
Guo J, Wu K, Ma Z, Guo S, Wang F, Lu L.
europepmc   +1 more source

Regulating Lipid Metabolism in Cancer: The Therapeutic Potential of Traditional Chinese Medicine

Phytotherapy Research, EarlyView.
By regulating the reprogramming of lipid metabolism in tumor cells, TCM provides a novel strategy for antitumor therapy with reduced toxicity and enhanced efficacy. ABSTRACT Lipid metabolic reprogramming is a key feature of tumor cells to adapt to the microenvironment and plays an important role in tumor growth, invasion, and metastasis.
Yufeng Gao, Huiming Huang, Xuejiao Wei, Xiaoxue Wang, Wanying Xie, Xinyu Qiu, Fei Wang, Zhuguo Wang, Ruoxin Zhang, Yilin Cai, Changhai Qu, Zhongdong Hu   +11 more
wiley   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source